Dupixent (Dupilumab), Sanofi’s New Targeted Therapy For Chronic Spontaneous Urticaria Approved by the U.S. FDA
Phase 3 tests showing Dupixent dramatically decreased itching and hives when compared to a placebo led to approval.
Tag: Sanofi
Sanofi’s Investigational New Drug Tolebrutinib for Multiple Sclerosis Shows Positive Results in Phase 3 Trials
Tolebrutinib was generally well tolerated by all subjects across all study arms.
U.S. FDA Approved Sanofi’s Qfitlia to Treat Hemophilia
In order to help hemophiliacs regain hemostasis, Qfitlia helps boost thrombin production by decreasing AT, a protein that prevents blood clotting.
